home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2779.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
48 lines
Document 2779
DOCN M94A2779
TI Immunotherapy with rgp160 (VaxSyn), and AZT, in asymptomatic
HIV-infected individuals.
DT 9412
AU Aiuti F; Pontesilli O; Guerra E; Ricci G; Varani AR; Carlesimo M; Scala
E; Mollicone B; Giovannetti A; Pandolfi F; et al; Univ. of Rome La
Sapienza, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):227 (abstract no. PB0337). Unique
Identifier : AIDSLINE ICA10/94369796
AB OBJECTIVE: To evaluate the effects of gp160 (VaxSyn, MicroGeneSys Inc.,
Meridien CT, USA) immunotherapy in association or not with AZT on safety
and immuno-virological markers, in asymptomatic HIV-infected patients
with CD4 counts > 400 and < 600 cells/mm3. METHODS: 100 patients have
been randomized to 3 treatment groups: 1) VaxSyn+Placebo AZT, 2)
VaxSyn+AZT, 3) Placebo VaxSyn (Alum)+AZT. Immunological response, viral
load, clinical evolution of disease, adverse experiences and
reactogenicity are monitored. RESULTS: Characteristics at entry of the
patients are: mean age 31.9 years (+/- 6.0); 69 males, 31 females. Of
151 study events reported 33 (21.8%) were minor discomforts at injection
site, headache was reported 27 times (17.8%), and nausea 12 times
(7.9%). At entry, CD4 cells were 487 +/- 99/mm3 and CD8 cells 1052 +/-
534/mm3. No significant changes were observed after six months of
treatment in the whole study population (473 +/- 87 and 965 +/- 499
cells/mm3 respectively). The ratio CD45RA+/CD45R0+ in the CD4 lymphocyte
population was 1.42 +/- 0.86 at entry and 1.50 +/- 0.76 after six
months. Lymphoproliferative response to gp160 was found in 13.1% of the
subjects at enrollment and a significant increase of it in 44% after 3-6
months of treatment. DISCUSSION AND CONCLUSIONS: The results of 9 months
of follow-up indicate that association of VaxSyn and AZT treatment is
well tolerated. Modifications of env-specific responses and no major
changes of immunological parameters are seen in the study population
after 6 months. Unblinded analysis of laboratory data and long-term
follow-up of the patients are needed to assess treatment efficacy.
DE Adult AIDS Vaccines/ADVERSE EFFECTS/*THERAPEUTIC USE Combined Modality
Therapy Comparative Study Female Gene Products, env/ADVERSE
EFFECTS/*THERAPEUTIC USE Human HIV Infections/DRUG THERAPY/*THERAPY
*Immunotherapy, Active Leukocyte Count Male Protein
Precursors/ADVERSE EFFECTS/*THERAPEUTIC USE Recombinant
Proteins/ADVERSE EFFECTS/THERAPEUTIC USE T-Lymphocyte Subsets
Treatment Outcome Vaccines, Synthetic/ADVERSE EFFECTS/*THERAPEUTIC USE
Zidovudine/*THERAPEUTIC USE CLINICAL TRIAL MEETING ABSTRACT
RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).